<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02759913</url>
  </required_header>
  <id_info>
    <org_study_id>IronHorseDx001</org_study_id>
    <nct_id>NCT02759913</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate the Performance of a Diagnostic Test in ALS</brief_title>
  <official_title>A Study to Evaluate the Sensitivity, Specificity, and Overall Accuracy of an Amyotrophic Lateral Sclerosis Diagnostic Test Developed by Iron Horse Diagnostics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Iron Horse Diagnostics, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Iron Horse Diagnostics, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Prospective multicenter study of subjects who were recently diagnosed with amyotrophic
      lateral sclerosis (ALS) or another neurodegenerative disease (including spinal cord diseases,
      muscle diseases and neurological diseases such as multiple sclerosis, multifocal motor
      neuropathy, myasthenia gravis and spinal muscular atrophy) or who are currently undergoing
      diagnostic procedures for the aforementioned diseases.

      Approximately 300 subjects will be enrolled. Subjects will undergo a lumbar puncture (LP) for
      cerebro-spinal fluid (CSF) collection; blood collection for serum, plasma, RNA, and DNA
      (optional); urine collection (optional); and skin biopsy (optional) in a single visit. No
      study treatment will be administered.

      Subjects will be managed and treated by their respective physicians; choice of therapy or
      laboratory tests will not be impacted by the study. Clinical diagnosis may be confirmed by
      the subject's physician and communicated to the study's Principal Investigator (PI) by
      scheduled telephone calls.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ALS, also known as Lou Gehrig's disease, is a rapidly progressive, degenerative disease of
      motor neurons in the brain and spinal cord that leads to muscle atrophy and spasticity in
      limb and bulbar muscles. Clinical presentations of this fatal disease include weakness, loss
      of ambulation, oropharyngeal dysfunction, weight loss, and ultimately respiratory failure.
      Average survival is approximately 3 years after symptom onset. The initial symptoms are
      similar to other neuropathies (e.g., motor neuropathy, progressive muscle atrophy, etc.) and
      include limb weakness leading to partial or total paralysis, and increasing difficulties in
      speech and breathing. ALS clinical diagnosis typically takes 12 months from symptom onset and
      relies on exclusion of other potential causes of the clinical symptoms. To date there are no
      FDA-approved diagnostic tests for ALS. Diagnostic tools for accurate and early diagnosis are
      under investigation. These tools would not only permit early intervention, but also would
      improve clinical trial design for new drug therapies.

      Axonal degeneration and inflammation are among proposed pathogenic mechanisms for ALS;
      therefore, proteins that function within these pathways are being evaluated as potential
      biomarkers. Iron Horse Diagnostics, Inc. (Iron Horse) has focused its ALS diagnostic efforts
      on studying the levels of cytoskeletal and inflammatory proteins in the cerebrospinal fluid
      (CSF) of ALS patients.

      Cytoskeletal proteins, including neurofilament proteins and tau, have been shown to be
      elevated in the CSF of patients with various neurodegenerative diseases. Interestingly,
      levels of phosphorylated neurofilament heavy subunit (pNfH) have been found to be
      significantly increased in the CSF of ALS patients as compared with healthy subjects,
      Alzheimer's disease patients or disease mimics Numerous inflammatory proteins, including
      cytokines and complement proteins, have been shown to be altered in ALS; complement proteins,
      including complement c3 (C3), have been found to be increased in the CSF of ALS patients.

      Iron Horse has evaluated CSF samples from 106 subjects (45 ALS patients, 25 disease controls
      with a range of neurodegenerative conditions, and 36 healthy controls.CSF levels of pNfH,
      tau, C3, and C reactive protein (CRP) were measured. pNfH was significantly elevated in CSF
      from ALS subjects as compared with healthy and disease controls; there were no significant
      differences for CRP or tau. To further distinguish between ALS subjects and disease controls,
      data from cytoskeletal and inflammatory pathways were combined. A ratio of CSF levels of pNfH
      and C3 showed significant differences between ALS and both the disease and healthy control
      groups. Results were verified on a separate test set of CSF samples. Overall, the predictive
      pNfH/C3 ratio identified ALS with 87.3 % sensitivity and 94.6% specificity in a total of 71
      ALS subjects, 52 disease control subjects, and 40 healthy subjects.

      In the same study, it was observed that plasma levels of pNfH were significantly elevated in
      ALS subjects as compared with healthy controls; however there was no significant difference
      between ALS and disease controls. Comparison of pNfH levels between the CSF and plasma for
      each study subject revealed a weak correlation between plasma and CSF pNfH levels.

      The accuracy of pNfH and pNfH/C3 ratio as ALS predictors has also been tested by Iron Horse
      in a recent prospective, blinded study in collaboration with the Northeast ALS Consortium
      (NEALS) [unpublished data]. CSF (n=126) and plasma (n=220) samples were collected from
      subjects from 30 medical centers across the United States (US) who were undergoing diagnostic
      assessment for neurodegenerative conditions or who were recently diagnosed with ALS. Accuracy
      for predicting ALS diagnosis was 93% for CSF pNfH/C3 ratio and 82% for pNfH plasma levels.

      The prospective study proposed in this concept will test the sensitivity, specificity, and
      overall accuracy of pNfH and pNfH/C3 ratio as ALS predictors on a separate sample set. CSF
      and matching plasma samples will be collected at up to 6 neurodegenerative clinics from up to
      300 subjects who were recently diagnosed with ALS or another similar neurologic disease or
      who are currently undergoing diagnostic procedures.
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2015</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">August 2016</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Biomarker Measurement of phosphorylated neurofilament heavy chain (pNfH) and complement C3 in CSF</measure>
    <time_frame>Baseline</time_frame>
    <description>Sensitivity, specificity, and overall accuracy of cerebro-spinal fluid (CSF) phosphorylated neurofilament (pNfH) pNfH/C3 ratio to identify ALS in a cohort of subjects who were recently diagnosed with ALS or another neurodegenerative disease or who are currently undergoing diagnostic procedures in the US. These are quantitative measurements of 2 proteins (pNfH) and C3 in cerebrospinal fluid (CSF), pNfH and C3 measurements will be reported in ng/ml and a single quantitative protein measurement of pNfH in ng/ml in plasma. In CS. The ratio of pNfH to C3 will be determined, both measurements for pNfH and C3 in CSF were made in ng/ml. In addition, the single biomarker measurements of pNfH and C3 in ng/ml will be presented. These biomarkers will be measured post-hoc and not for diagnostic decisions.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ALS Functional Rating Scale (ALSFRS-R)</measure>
    <time_frame>At baseline</time_frame>
    <description>ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">300</enrollment>
  <condition>Amyotrophic Lateral Sclerosis (ALS)</condition>
  <arm_group>
    <arm_group_label>Amyotrophic lateral sclerosis</arm_group_label>
    <description>Participants recently diagnosed with ALS in a neuromuscular clinic, using the ALS functional rating scale (ALSFRS-R). Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection The ALSFRS-R is a quickly administered (5 min) ordinal rating scale used to determine a subject's assessment of their capability and independence in 12 functional activities. There are 12 questions, graded by the subject 0-4 (4 is normal). Score of 0 (worst) to 48 (best). Reflects speech and swallowing, fine motor skills, large motor skills, and breathing.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>ALS mimics</arm_group_label>
    <description>Other motorneuron disorders, isolated upper and lower motoneuron disorders Lumbar puncture (LP) for cerebro-spinal fluid (CSF) collection</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Lumbar puncture</intervention_name>
    <description>Collection of biofluids to determine the accuracy, sensitivity and specificity of a diagnostic test developed by Iron Horse Diagnostics</description>
    <arm_group_label>Amyotrophic lateral sclerosis</arm_group_label>
    <arm_group_label>ALS mimics</arm_group_label>
  </intervention>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Cerebrospinal fluid, EDTA plasma, serum, whole blood (optional) and PAX gene tubes will be
      collected
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        ALS and other motoneuron diseases (ALS mimics)
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  To be eligible to participate in this study, candidates must meet the following
             eligibility criteria at the Screening Visit:

               1. Ability to understand the purpose and risks of the study and provide signed and
                  dated informed consent and authorization to use protected health information
                  (PHI) in accordance with national and local subject privacy regulations.

               2. Aged 21 to 80 years old, inclusive.

               3. Must meet one of the following:

                    -  Recent diagnosis of sporadic or familial ALS (within 18 months of first
                       visit for ALS symptoms) according to the World Federation of Neurology El
                       Escorial criteria (revised according to the Airlie House Conference 1998
                       [Brooks 1999] ).

                    -  Recent diagnosis of neuromuscular disease other than ALS (within 12 months
                       of first visit for neurologic symptoms).

                    -  Undergoing diagnostic procedures for neuromuscular disease.

               4. Willingness and medical ability to comply with scheduled visits, LP for CSF
                  collection, laboratory tests, and other study procedures.

        Exclusion Criteria:

          -  Candidates will be excluded from study entry if any of the following exclusion
             criteria exist at the Screening Visit:

               1. Any contraindications to having an LP, including but not limited to:

                    -  Platelet count &lt;100,000/ÂµL.

                    -  History of bleeding disorder.

                    -  Use of platelet antiaggregant or anticoagulant drugs, including but not
                       limited to clopidogrel, dipyridamole, ticlopidine , and warfarin. Use of
                       aspirin at a prophylactic dose of 75-325 mg r less is acceptable.

                    -  History of intolerance to the LP procedure.

                    -  Evidence of topical or other skin infection at the LP site.

                    -  Prior spinal fusion surgery or other spinal surgery at the LP site.

               2. If undergoing skin biopsy, evidence of topical or other skin infection at the
                  biopsy site.

               3. History of allergy or other adverse reaction to local anesthetics used in the
                  study.

               4. History of traumatic central nervous system injury or stroke.

               5. History of chronic liver or renal failure.

               6. Requirement for artificial respiration, including tracheostomy and any use of
                  bilevel positive airway pressure (BiPAP) therapy.

               7. Female subjects who are pregnant or currently breastfeeding.

               8. Current enrollment in any other investigational drug, medical devices, or disease
                  study.

               9. Other unspecified reasons that, in the opinion of the Investigator or Iron Horse,
                  make the subject unsuitable for enrollment.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Andreas Jeromin, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Iron Horse Diagnostics</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Andreas Jeromin, PhD</last_name>
    <phone>3526727358</phone>
    <email>andreasjeromin@ironhorsedx.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cleveland Clinic</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44195</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Irys Caristo</last_name>
      <phone>261-444-0173</phone>
      <email>caristi@ccf.org</email>
    </contact>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 4, 2016</study_first_submitted>
  <study_first_submitted_qc>April 29, 2016</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 3, 2016</study_first_posted>
  <last_update_submitted>April 29, 2016</last_update_submitted>
  <last_update_submitted_qc>April 29, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">May 3, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Iron Horse Diagnostics, Inc.</investigator_affiliation>
    <investigator_full_name>Andreas Jeromin</investigator_full_name>
    <investigator_title>Chief Scientific Officer</investigator_title>
  </responsible_party>
  <keyword>neuromuscular diseases</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Sclerosis</mesh_term>
    <mesh_term>Motor Neuron Disease</mesh_term>
    <mesh_term>Amyotrophic Lateral Sclerosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

